Ironwood Pharmaceuticals' stock fell 14.5% following the CFO's resignation and insider selling, creating a contrarian buying opportunity. Despite this short-term volatility, the company's fundamentals remain strong, supported by steady cash flow and a profit-sharing revenue model with AbbVie for LINZESS. Analysts see potential for the stock to nearly double from its current price of $3.49 to a target of $6.90. The recent management changes and insider sales have caused temporary market uncertainty, but the underlying business model and earnings potential remain solid for long-term investors.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
